GPP
DRUG

Great Point Partners’s Bright Minds Biosciences DRUG Stock Holding History

Great Point Partners’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.1M Buy
+220,000
New +$17.7M 3.69% 9

Other funds holding DRUG

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Great Point Partners's DRUG Position: Q1 2026 in Review

Great Point Partners opened a new position in Bright Minds Biosciences (DRUG) in Q1 2026: 220,000 shares worth $16.1M. The stake represents 3.69% of the portfolio and ranks #9 among its holdings.

94 funds tracked by Wall St. Rank hold DRUG as of Q1 2026.

  • Great Point Partners held 220,000 shares of Bright Minds Biosciences worth $16.1M as of Q1 2026.
  • Bright Minds Biosciences was a new Great Point Partners position in Q1 2026.
  • Bright Minds Biosciences made up 3.69% of Great Point Partners's portfolio in Q1 2026, its #9 holding.
  • 94 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q1 2026.

Based on Great Point Partners's 13F filing for Q1 2026, filed 15 May 2026.